EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterprise
EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs
Provides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery network
EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
EQRx, Inc. (Nasdaq: EQRX), announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET.
EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices
Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceeds
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination
EQRx and CM Life Sciences III Inc. (Nasdaq: CMLTU), a life science-focused special purpose acquisition company, or SPAC, announced that the U.S. Securities and Exchange Commission (“SEC”) has declared CM Life Sciences III’s registration statement on Form S-4 relating to the previously announced business combination agreement between EQRx and CM Life Sciences III effective.